22 March 2024
Aptamer
Group plc
("Aptamer", the "Company" or the "Group")
Notice of Results and
Investor Presentation
Aptamer Group plc (AIM: APTA), the developer of
novel Optimer® binders to enable innovation in
the life sciences industry, will announce its interim results for
the six months ended 31 December 2023 on 28 March 2024.
The Company is pleased to announce
that Dr Arron Tolley (Chief Technical Officer), Dr David Bunka
(Chief Scientific Officer) and Andrew Rapson (Chief Financial
Officer) will provide a live presentation relating to the Interim
Results via Investor Meet Company on 28 March 2024 at 15:00
GMT.
The live presentation is open to all
existing and potential shareholders. Questions can be submitted
pre-event via your Investor Meet Company dashboard up until 27
March 2024 at 09:00 GMT, or at any time during the live
presentation.
Investors can sign up to Investor
Meet Company for free and add to meet Aptamer Group Plc
via:
https://www.investormeetcompany.com/aptamer-group-plc/register-investor
Investors who already follow Aptamer
Group Plc on the Investor Meet Company platform will automatically
be invited.
- ENDS
-
For further information, please
contact:
|
Aptamer Group plc
Steve Hull
|
+44 (0) 1904 217 404
|
|
SPARK Advisory Partners Limited -
Nominated Adviser
Andrew Emmott / Mark Brady / Adam
Dawes
|
+44 (0) 20 3368 3550
|
|
Turner
Pope Investments
(TPI) Limited - Broker
James Pope /
Andrew Thacker
|
+44 (0) 20 3657 0050
|
About Aptamer Group plc
Aptamer Group develops custom affinity binders through its proprietary
Optimer® platform to enable
new approaches in therapeutics, diagnostics, and research
applications. The Company strives to deliver transformational
solutions that meet the needs of life science researchers and
developers.
Optimer binders are oligonucleotide
affinity ligands that can function as an antibody alternative. The
global affinity ligand market is currently worth over $170
billion.
Aptamer has successfully delivered
projects for a range of global pharma companies, diagnostic
development companies, and research institutes, covering multiple
application areas with the objective of establishing
royalty-bearing licenses.